Advocacy

Opioids

Access to Opioid Addiction Medications Toolkit

Buprenorphine/naloxone, buprenorphine, methadone and extended-release injectable naltrexone are FDA-approved medications shown to be highly effective in the treatment of opioid addiction, a chronic, life-threatening disease that affects millions of Americans. As with most chronic diseases, opioid addiction often requires long-term medication maintenance to achieve optimal outcomes. Many patients - like Whitney, Eva and Walter - who receive medication assisted opioid addiction treatment do recover and lead healthy and productive lives. Use the resources below to help you advocate for increased access to medications to treat opioid addiction. 

Talking Points

Research and Reports

Policy Resources

Naloxone Toolkit

Drug overdoses are the current leading cause of accidental death in the U.S., having surpassed traffic fatalities. Opioid addiction is driving this epidemic. In 2014 there were 47,055 lethal drug overdoses, with 18,893 overdose deaths related to prescription opioid analgesics and 10,574 overdose deaths related to heroin. Naloxone is an FDA-approved opioid antagonist that can reverse the effects of an opioid overdose, thus saving the life of the overdose victim when administered in time. Use these resources to advocate for providing opioid overdose education and naloxone to persons who use drugs and who might be present at an opioid overdose in order to reduce opioid overdose mortality. 

Talking Points

  • Naloxone Talking Points (ASAM) Use these talking points to help guide your discussions with policymakers about access to and increased use of naloxone.

Research and Reports

Policy Resources

Please see ASAM's National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use for clinical guidance on the use of all three FDA-approved medications to treat opioid addiction and the use of naloxone to prevent opioid overdose deaths.